-
Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M, 2005: In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocyte by DNA vaccine-primed cytotoxic T lymphocyte[J]. J Infec Dis, 192, 2112-2116. doi: 10.1086/jid.2005.192.issue-12
-
Ahlen G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, Sällberg M, 2007: In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells[J]. J Immunol, 179, 4741-4753. doi: 10.4049/jimmunol.179.7.4741
-
Andre S, Seed B, Eberle J, Schraut W, Bültmann A, Haas J, 1998: Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage[J]. J Virol, 72, 1497-1503.
-
Arribillaga L, de Cerio A L, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borrás-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte J J, 2002: Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV recombinant vaccinia virus[J]. Vaccine, 21, 202-210. doi: 10.1016/S0264-410X(02)00456-5
-
Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H, 1993: Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions[J]. J Virol, 67, 3835-3844.
-
Bocher W O, Dekel B, Schwerin W, Geissler M, Hoffmann S, Rohwer A, Arditti F, Cooper A, Bernhard H, Berrebi A, Rose-John S, Shaul Y, Galle P R, F L?hr H, Reisner Y, 2001: Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection[J]. Eur J Immunol, 31, 2071-2079. doi: 10.1002/(ISSN)1521-4141
-
De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G, 2003: Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA dependent RNA polymerase[J]. J Antiviral Res, 58, 1-16. doi: 10.1016/S0166-3542(03)00028-7
-
Encke J, zuPutlitz J, Geissler M, Wands J R, 1998: Genetic Immunization generates cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model[J]. J Immunol, 1, 4917-4923.
-
Feltquate D M, Heaney S, Webster R G, Robinson H L, 1997: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization[J]. J Immunol, 158, 2278-2284.
-
Foy E, Li K, Sumpter R, Loo Y M, Johnson C L, Wang C, Fish P M, Yoneyama M, Fujita T, Lemon S M, Gale M Jr, 2004: Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling[J]. PNAS, 102, 2986-2991.
-
Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, Sällberg M, 2004: Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene[J]. J Gene Ther, 11, 522-533. doi: 10.1038/sj.gt.3302184
-
Frick D N, 2007: The hepatitis C virus NS3 protein: a model RNA helicase andpotential drug target[J]. Curr Issues Mol Biol, 9, 1-20.
-
Gao M, Wang H P, Wang Y N, Zhou Y, Wang Q L, 2006: HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo[J]. Vaccine, 24, 5491-5497. doi: 10.1016/j.vaccine.2006.04.004
-
Geissler M, Gesien A, Tokushige K, Wands J R, 1997: Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine expressing plasmids[J]. J Immunol, 158, 1231-1237.
-
Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi M, Ebtekar E, 2007: Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice[J]. J Comp immunol microbiol Infect Dis, 30, 197-210. doi: 10.1016/j.cimid.2007.01.002
-
Ghaemi A, Soleimanjahi H, Gill P, Zuhair H, Razeghi M, Jahromi S, Roohvand F, 2010: Recombinant λ-phage nanobioparticles for tumor therapy in mice models[J]. J Genet Vaccines Ther, 8, 1-7.
-
Ghaemi A, Soleimanjahi H, Gill P, Zuhair M H, Razeghi S, Fazeli M, Razavinikoo S M H, 2009: Protection of Mice by a -Based Therapeutic Vaccine against Cancer Associated with Human Papillomavirus Type 16[J]. J Intervirol, 54, 105-112.
-
Gherardi M M, Ramirez J C, Esteban M, 2000: Interleukin-12 (IL-12) Enhancement of the Cellular Immune Response against Human Immunodeficiency Virus Type 1 Env Antigen in a DNA Prime/Vaccinia Virus Boost VaccineRegimen Is Time and Dose Dependent: Suppressive Effects of IL-12 Boost Are Mediated by Nitric Oxide[J]. J Virol, 74, 6278-6286. doi: 10.1128/JVI.74.14.6278-6286.2000
-
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S, 2002: Antigen presentation and T cell stimulation by dendritic cells[J]. J Annu Rev Immunol, 20, 621-667. doi: 10.1146/annurev.immunol.20.100301.064828
-
Gurunathan S, Klinman D M, Seder R A, 2000: DNA vaccines: immunology, application, and optimization[J]. Annu Rev Immunol, 18, 927-974. doi: 10.1146/annurev.immunol.18.1.927
-
Ha S J, Jeon B Y, Kim S C, Kim D J, Song M K, Sung Y C, Cho S N, 2003: Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with mycobacterium tuberculosis[J]. J Gene Ther, 10, 1543-. doi: 10.1038/sj.gt.3302042
-
Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K, 1993: Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus[J]. J Virol, 67, 4665-4675.
-
Jiao X, Wang R Y, Feng Z, Hu G, Alter H J, Shih J W-K, 2004: DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response[J]. J Viral Hepatol, 11, 18-26. doi: 10.1046/j.1352-0504.2003.00464.x
-
Kim J J, Ayyavoo V, Bagarazzi M L, Chattergoon M A, Dang K, Wang B, Boyer J D, Weiner D B, 1997: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen[J]. J Immunol, 158, 816-826.
-
Kieper W C, Tan J T, Bondi-Boyd B, Gapin L, Sprent J, Ceredig R, Surh C D, 2002: Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells[J]. J Exp Med, 195, 1533-. doi: 10.1084/jem.20020067
-
Kieper W C, Prlic M, Schmidt C S, Mescher M F, Jameson S C, 2001: Il-12 enhances CD8+ T cell homeostatic expansion[J]. J Immunol, 166, 5515-. doi: 10.4049/jimmunol.166.9.5515
-
Koff R S, 2003: Hepatitis vaccines: recent advances[J]. Int J Parasitol, 33, 517-523. doi: 10.1016/S0020-7519(03)00065-1
-
Lanford R E, Guerra B, Chavez D, Bigger C, Brasky K M, Wang X H, Ray S C, Thomas D L, 2004: Cross-genotype immunity to hepatitis C virus[J]. J Virol, 78, 1575-1581. doi: 10.1128/JVI.78.3.1575-1581.2004
-
Lang K A, Yan J, Draghia-Akli R, Khan A, Weiner D B, 2008: Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine[J]. Vaccine, 26, 6225-6231. doi: 10.1016/j.vaccine.2008.07.052
-
Lauer G M, Walker B D, 2001: Hepatitis C virus infection[J]. N Engl J Med, 345, 41-52. doi: 10.1056/NEJM200107053450107
-
Martin T, 1999: Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection[J]. Hum Gene Ther, 10, 759-768. doi: 10.1089/10430349950018517
-
Nichols W W, 1995: Potential DNA vaccine integration into host cell genome[J]. Ann N Y Acad Sci, 772, 30-39. doi: 10.1111/nyas.1995.772.issue-1
-
Semmo N, Day C L, Ward S M, Lucas M, Harcourt G, Loughry A, Klenerman P, 2005: Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection[J]. J Hepatol, 41, 1019-1102. doi: 10.1002/(ISSN)1527-3350
-
Pang P S, Jankowsky E, Planet P J, Pyle A M, 2002: The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding[J]. EMBO J, 21, 1168-1176. doi: 10.1093/emboj/21.5.1168
-
Pawlotsky J M, 2009: Hepatitis: HCV variability, the immune system and resistance to antiviral drugs[J]. Nat Rev Gastroenterol Hepatol, 6, 383-385. doi: 10.1038/nrgastro.2009.102
-
Schmidt C S, Mescher M F, 1999: Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD81 T cells in vivo[J]. J Immunol, 163, 2561-.
-
Scott P, Trinchieri G, 1997: IL-12 as an adjuvant for cell-mediated immunity[J]. Semin J Immunol, 9, 285-291. doi: 10.1006/smim.1997.0084
-
Sin J I, Kim J J, Arnold R L, Shroff K E, McCallus D, Pachuk C, McElhiney S P, Wolf M W, Pompa-de Bruin S J, Higgins T J, Ciccarelli R B, Weiner D B, 1999: IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity against Herpes Simplex Virus-2 Challenge[J]. J Immunol, 162, 2912-2921.
-
Shan M M, Liu K Z, Fang H L, Chen Z, 2002: DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigen[J]. HBPD INT, 1, 553-557.
-
Tokushige K, Wakita T, Pachuk C, Moradpour D, Wener D B, Zurawski J R V R, Wands J R, 1996: Expression and Immune Response to Hepatitis C Virus Core DNA-Based Vaccine Constructs[J]. J Hepatol, 24, 14-20. doi: 10.1002/(ISSN)1527-3350
-
Weck K, 2005: Molecular methods of hepatitis C genotyping[J]. Expert Rev Mol Diagn, 5, 507-520. doi: 10.1586/14737159.5.4.507
-
Weiner A J, Paliard X, Selby M J, Medina-Selby A, Coit D, Nguyen S, Kansopon Joe, L Arian Ch, Ng Ph, Tucker Jeffery, Lee Ch-T, K Polakos N, Han J, Wong Sh, Lu H-H, Rosenberg S, M Brasky K, Chien D, Kuo G, Houghton M, 2001: Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity[J]. J Virol, 75, 7142-7148. doi: 10.1128/JVI.75.15.7142-7148.2001
-
Xiang Z, Ertl H C, 1995: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines[J]. J Immunity, 2, 129-135. doi: 10.1016/S1074-7613(95)80001-8
-
Yang S H, Lee C G, Park S H, Im S J, Kim Y M, Son J M, Wang J S, Yoon S K, Song M K, Ambrozaitis A, Kharchenko N, Yun Y D, Kim C M, Kim C Y, Lee S H, Kim B M, Kim W B, Sung Y C, 2006: Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study[J]. J Gene Ther, 13, 1110-1117. doi: 10.1038/sj.gt.3302751